Sanofi Board Votes Unanimously to Oust CEO Viehbacher

The video discusses the recent departure of Santa Fe's CEO, Chris via backer, and the implications for the company. It covers the company's strategy, board relations, and stock performance, highlighting investor sentiment and recent downgrades. The discussion also touches on sales figures, competitive pressures, and market dynamics, particularly concerning the drug Lantis, which faces pricing competition. The video concludes with a look at the future outlook for the company.

What were the circumstances surrounding the CEO's departure?

What impact did the CEO's strategy have on investor sentiment?

How did the company's stock perform prior to the CEO's departure?

What changes were made in the company's focus from small molecules to biologics?

What competitive pressures is the company facing regarding its products?